Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Scalp cooling significantly reduces hair loss in chemotherapy patients.

In this study, the Orbis PAXMAN® scalp cooling system showed effectiveness and good tolerability in preventing chemotherapy-induced hair loss in breast cancer patients, particularly those receiving anthracycline-free chemotherapy, though the presence of comorbidities was linked to a higher risk of severe alopecia.

This study found that combining the PAXMAN scalp cooling system with HairRepro MEDI α lotion led to a 50% success rate in reducing chemotherapy-induced alopecia and achieved complete hair regrowth by 3 months in Japanese breast cancer patients, suggesting enhanced efficacy over scalp cooling alone.

In this study, scalp cooling therapy was found to be well tolerated and effective at improving hair preservation for Asian women with breast or gynecological cancers undergoing certain chemotherapy regimens, particularly weekly paclitaxel, compared to historical controls.

This study outlines the temporary or sometimes permanent hair loss caused by cancer treatments, noting it often starts 2-3 weeks after chemotherapy and highlights the need for more research into prevention and treatment strategies for therapy-related alopecia.